Developmental Research Program

发展研究计划

• 批准号: 10434092
• 负责人: Iannis Aifantis
• 金额: $ 7.88万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-07-19 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10434092
• 关键词: Area; Award; Cancer Center; Cessation of life; Clinical Management; Development; Diagnosis; Disease Progression; Ensure; Epidemiology; Evaluation; Extramural Activities; Funding; Funding Mechanisms; Genetic; Goals; Growth; Health; International; Investigation; Investigator-Initiated Research; Malignant Neoplasms; Mentorship; Mission; Molecular; Monitor; Pathology; Patients; Pilot Projects; Positioning Attribute; Prognosis; Program Research Project Grants; Research; Research Personnel; Research Project Grants; Translational Research; Work; biomarker discovery; disorder risk; high reward; high risk; improved; innovation; melanoma; novel; novel strategies; personalized management; professor; programs; recruit; screening; success; translational potential; translational study

PROJECT SUMMARY The overall goal of the NYU Melanoma SPORE Developmental Research Program (DRP) is to support pilot projects that take maximum advantage of new research opportunities in melanoma and aid in recruiting established cancer investigators at the level of Assistant Professor or higher to the translational study of melanoma. The DRP focuses on and will select innovative and promising translational research projects in melanoma, and will monitor their progress to ensure that goals are met. The Director of the DRP is Dr. Iannis Aifantis, the Chair of the NYU Department of Pathology and an internationally regarded investigator who brings an accomplished track record of mentorship and emerging translational melanoma research success. He will work together with an internal evaluation panel and the SPORE PD/PIs to identify and support selected pilot studies with exceptional translational potential. The NYU Melanoma SPORE DRP will support projects for up to 2 years, enabling awardees to adequately explore the potential of novel topics in translational melanoma research. Focusing on innovation, the DRP will support the development of “high-risk, high-reward” investigations in melanoma and encourage proposals for novel approaches to screening, diagnosis, prognosis, prediction, and treatment of melanoma. The DRP will monitor the progress of all projects and awardees chosen for funding to ensure that goals are met and that DRP projects may be strongly positioned to replace any SPORE project either not meeting its translational research goals or completed prior to the close of the award period. The DRP is highly integrated thematically and programmatically with the larger NYU Melanoma SPORE and recognizes that a key component to the growth of the SPORE is the continued support and development of novel investigations in melanoma, specifically in the area of improved personalized management of melanoma patients. Both NYU Langone Health (NYULH) and the NYU Perlmutter Cancer Center (PCC) have consistently used various pilot funding mechanisms to support promising novel approaches to melanoma prognosis, clinical management, and treatment.

项目摘要 NYU黑色素瘤孢子发育研究计划（DRP）的总体目标是支持飞行员 最大程度地利用黑色素瘤新研究机会并有助于招募的项目 在助理教授级别或更高级别的癌症研究者的转化研究水平 黑色素瘤。 DRP专注于并将选择创新和有前途的翻译研究项目 黑色素瘤，并将监测他们的进度以确保实现目标。 DRP的主任是Iannis博士 纽约大学病理部主席Aifantis和国际考虑的调查员带来了 心态和新兴转化黑色素瘤研究成功的良好记录。他会的 与内部评估面板和孢子PD/PI一起工作，以识别和支持选定的飞行员 具有非凡的翻译潜力的研究。 NYU黑色素瘤孢子DRP将支持UP的项目 到2年 研究。 DRP专注于创新，将支持“高风险，高级奖励”的发展 黑色素瘤的研究并鼓励提出有关筛查，诊断，预后的新方法的建议 预测和治疗黑色素瘤。 DRP将监视所有项目和获奖者的进度 为了确保实现目标，并且DRP项目可能会替代任何目标，以取代任何目标 孢子项目要么不实现其转化研究目标，要么在奖励结束之前完成 时期。 DRP与较大的NYU黑色素瘤孢子和编程性地高度集成 认识到孢子增长的关键组成部分是持续的支持和发展 黑色素瘤的新型研究，特别是在改善黑色素瘤的个性化管理领域 患者。 NYU Langone Health（NYULH）和NYU Perlmutter癌症中心（PCC）始终如一 使用各种试点资金机制来支持有望的新型黑色素瘤预后方法，临床 管理和治疗。